

Midkine - Pipeline Review, H1 2020

<https://marketpublishers.com/r/MDA98EF515A8EN.html>

Date: February 2020

Pages: 44

Price: US\$ 3,500.00 (Single User License)

ID: MDA98EF515A8EN

Abstracts

Midkine - Pipeline Review, H1 2020

SUMMARY

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Midkine (MDK) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation. It is involved in neointima formation after arterial injury and early fetal adrenal gland development.

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical stages are 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Genito Urinary System And Sex Hormones, Immunology, Gastrointestinal, Cardiovascular, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Inflammation, Kidney Fibrosis, Liver Fibrosis, Non-Small Cell Lung Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bone Disorders, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Fibrosis, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glomerulonephritis, Hypertension, Ischemia Reperfusion Injury, Kidney Disease (Nephropathy), Lung Disease, Neuroblastoma, Osteosarcoma, Prostate Cancer, Solid Tumor and Squamous Non-Small Cell Lung Cancer.

The latest report Midkine - Pipeline Review, H1 2020, outlays comprehensive information on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)

The report reviews Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics and enlists all their major and minor

projects

The report assesses Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Overview

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Molecule Type

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Companies Involved in Therapeutics Development

Cellmid Ltd

Ribomic Inc

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Drug Profiles

CAB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAB-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iMDK - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Midkine for Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Dormant Products

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Product Development Milestones

Featured News & Press Releases

Aug 22, 2019: Patent for improved Midkine antibody allowed in Europe

Sep 12, 2018: Cellmid's lead antibody effective in rare chronic kidney disease

Feb 07, 2017: Cellmid's European Midkine Patent For Alopecia Allowed

Jan 18, 2017: Cellmid Receives Australian Government Grant For Midkine Programme

Oct 05, 2016: Cellmid's Midkine Antibodies Show Anti-Tumour Activity against Brain Cancer

Jun 23, 2015: Cellmid Collaboration To Treat Brain Cancer

Jun 15, 2015: Cellmid'S Humanised Midkine Antibody Drug Is Safe In Toxicology Studies

Jul 15, 2014: Cellmid Granted UK Patent for Use of Midkine for Hair Growth

Oct 06, 2011: Cellmid Completes Humanization Of Anti-midkine Antibody In Collaboration With Antitope

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Cellmid Ltd, H1 2020
Pipeline by Ribomic Inc, H1 2020
Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Cellmid Ltd

Ribomic Inc

I would like to order

Product name: Midkine - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/MDA98EF515A8EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDA98EF515A8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970